今年上半年， 医院 的生意并不好做。 公告称，预期利润下降主要由于医保次均费用下降导致成员医疗机构经营利润下降。同时公司逐渐退出IOT(即投资-运营-移交模式)业务，其对应的利润贡 献下降。2025年下半年公司将继续积极改善收入结构，推动管理精细化，控制运营成本，提高经营效益。 值得注意的是，在2024年年报中，华润医疗也坦言，受医保控费影响，次均费用有所下降。 据官网信息不完全统计，公司医院业务覆盖10个省（区、市），其中三甲医院至少超9家。 据公司年报，截至2024年12月31日，有医疗机构105家，其中三级医院13家，二级医院22家，运营床位数合计20000余张。 | ็คือ | 三级医院 | 二级医院 | | --- | --- | --- | | 辽宁 | 抚矿总医院(三甲) | 沈煤总医院(二甲) | | | 本钢总医院(三甲) | 一五七医院(二甲) | | | 阜新矿总医院(三甲) | 辽核总医院(二甲) | | | 铁煤总医院(三甲) | | | 广东 | 广东三九脑科医院(三甲) | 广东中能建电力医院(二甲) | | 广西 | | 广西水电医院 | | 安徽 | 淮北矿工总医院(三甲) ...

Group 1 - The core business of hospitals is facing challenges in the first half of the year, with China Resources Medical (01515.HK) reporting a significant decline in patient visits and hospital admissions for 2024 [1][3] - The company anticipates a profit decline of approximately 20% to 25% for the first half of 2024, and a more severe drop of 55% to 60% when excluding one-time income from previous management fees and compensation [3] - The decline in profits is attributed to reduced average medical expenses due to healthcare insurance cost control, as well as the company's gradual exit from the investment-operation-transfer (IOT) model, which has impacted profit contributions [3] Group 2 - The company operates hospitals across 10 provinces, with at least 9 tertiary hospitals among its facilities [3][4] - The performance issues faced by China Resources Medical are not isolated, as International Medical (000516.SZ) also reported expected losses for the first half of 2025, influenced by market fluctuations and policy reforms [5] - International Medical's revenue for the first quarter of 2025 showed a decline of 14.99% year-on-year, with a net profit loss of 1.06 billion yuan, indicating broader industry challenges [5][6] Group 3 - The healthcare industry is undergoing significant changes with the full implementation of DRG/DIP payment systems, which are pressuring hospitals to reduce costs and improve efficiency [6] - Public hospitals are experiencing revenue pressure, while leading private hospitals may benefit from compliant operations, suggesting a potential market consolidation [6]

每经编辑｜金冥羽 今年上半年，医院的生意并不好做。 华润医疗（01515.HK）是华润集团旗下综合性医疗上市公司。2024年，公司自有医院常规门诊量和住院量分别为1032.56万人次和56.01万人次。 但在8月4日，公司股价低开7%后迅速下杀，截至午间收盘，股价跌15.8%，报3.73港元/股，市值约为48.4亿港元，成交额约为2.8亿港元。 消息面上，华润医疗（01515.HK）8月4日发布公告称，今年上半年，公司预料报告期的公司拥有人应占利润相较2024年同期下降约20%至25%；而经剔除 该公告所载有关集团一次性收到燕化IOT协议下以前年度管理费及供应链损失赔偿款项约人民币2.1亿元和对应的企业所得税后，公司拥有人应占利润相较 2024年同期下降约55%至60%。 公告称，预期利润下降主要由于医保次均费用下降导致成员医疗机构经营利润下降。同时公司逐渐退出IOT(即投资-运营-移交模式)业务，其对应的利润贡 献下降。2025年下半年公司将继续积极改善收入结构，推动管理精细化，控制运营成本，提高经营效益。 值得注意的是，在2024年年报中，华润医疗也坦言，受医保控费影响，次均费用有所下降。 图片来源：公司 ...

公告显示，利润下滑主要原因包括医保次均费用下降挤压医疗机构利润，以及公司逐步退出IOT业务导 致相关利润贡献减少。 北京商报讯（记者 王寅浩 实习记者 宋雨盈）8月4日，华润医疗发布公告称，预计2025年上半年公司拥 有人应占利润同比下降20%—25%；若剔除公告所载有关集团一次性收到燕化IOT协议下以前年度管理 费及供应链损失赔偿款项约2.1亿元和对应的企业所得税后，公司拥有人应占利润相较2024年同期下降 约55%—60%。 ...

Core Viewpoint - China Resources Medical (01515.HK) anticipates a decline in profit attributable to shareholders by approximately 20% to 25% for the six months ending June 30, 2025, compared to the same period in 2024. After excluding a one-time management fee and compensation of approximately RMB 210 million from the YanHua IOT agreement, the profit is expected to decrease by about 55% to 60% compared to 2024 [1] Group 1 - The expected profit decline is primarily due to a decrease in average medical expenses under the medical insurance system, leading to reduced operating profits for member medical institutions [1] - The company is gradually exiting the Investment-Operation-Transfer (IOT) business model, resulting in a corresponding decline in profit contribution [1] - In the second half of 2025, the company plans to actively improve its revenue structure, enhance management precision, control operating costs, and increase operational efficiency [1]

公告称，预期利润下降主要由于医保次均费用下降导致成员医疗机构经营利润下降。同时公司逐渐退出 IOT(即投资-运营-移交模式)业务，其对应的利润贡献下降。2025年下半年公司将继续积极改善收入结 构，推动管理精细化，控制运营成本，提高经营效益。 消息面上，8月4日，华润医疗发布公告，公司预料截至2025年6月30日止六个月的公司拥有人应占利润 相较2024年同期下降约20%至25%；而经剔除有关集团一次性收到燕化IOT协议下以前年度管理费及供 应链损失赔偿款项约人民币2.1亿元和对应的企业所得税后，公司拥有人应占利润相较 2024年同期下降 约55%至60%。 智通财经获悉，华润医疗(01515)盈警后低开7%，截至发稿，跌7%，报4.12港元，成交额415.91万港 元。 本文源自智通财经网 ...

港股医药股震荡走低，华润医疗跌超13%，石药集团、复星医药、微创医疗、药明康德、药明生物等跟 跌。 ...

8月4日，华润医疗(01515)盘中下跌8.35%，截至09:30，报4.06元/股，成交1651.07万元。 本文源自：金融界 作者：行情君 华润医疗控股有限公司是内地和香港两地规模领先的医疗上市公司，致力于专业化整合和资本化运作医 疗资源，其经营的医疗机构多达146家，运营床位数超过21985张。公司在2023年收购了母公司华润健康 的36家优质医疗机构，增强了医疗服务能力，并对集团化运营和精细化管理模式进行创新改良，以满足 人民群众的多样化医疗健康服务需求。 截至2024年年报，华润医疗营业总收入98.55亿元、净利润5.66亿元。 ...

公告称，预期利润下降主要由于医保次均费用下降导致成员医疗机构经营利润下降。同时公司逐渐退出 IOT(即投资-运营-移交模式)业务，其对应的利润贡献下降。2025年下半年公司将继续积极改善收入结 构，推动管理精细化，控制运营成本，提高经营效益。 智通财经APP获悉，华润医疗(01515)盈警后低开7%，截至发稿，跌7%，报4.12港元，成交额415.91万 港元。 消息面上，8月4日，华润医疗发布公告，公司预料截至2025年6月30日止六个月的公司拥有人应占利润 相较2024年同期下降约20%至25%；而经剔除有关集团一次性收到燕化IOT协议下以前年度管理费及供 应链损失赔偿款项约人民币2.1亿元和对应的企业所得税后，公司拥有人应占利润相较 2024年同期下降 约55%至60%。 ...

Core Viewpoint - China Resources Medical (01515) issued a profit warning, anticipating a profit decline of approximately 20% to 25% for the six months ending June 30, 2025, compared to the same period in 2024, with a more significant decline of about 55% to 60% when excluding one-time management fees and compensation related to the Yanhua IOT agreement [1][1][1] Group 1 - The company's stock opened lower by 7% and is currently trading at HKD 4.12, with a trading volume of HKD 4.1591 million [1][1] - The anticipated profit decline is primarily attributed to a decrease in average medical expenses under the medical insurance system, leading to reduced operating profits for member medical institutions [1][1][1] - The company is gradually exiting the IOT (Investment-Operation-Transfer) business, resulting in a decline in profit contributions from this segment [1][1][1] Group 2 - For the second half of 2025, the company plans to actively improve its revenue structure, enhance management precision, control operational costs, and increase operational efficiency [1][1][1]